Fractional flow reserve-guided percutaneous coronary intervention is not a valid concept

Circulation

Volumn 129, Issue 18, 2014, Pages 1871-1878

  Arbab Zadeh, Armin ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ARTICLE; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIUM SCORE; FRACTIONAL FLOW RESERVE; HEALTH CARE COST; HEART CATHETERIZATION; HEART MUSCLE PERFUSION; HUMAN; INVASIVE PROCEDURE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CORONARY CIRCULATION; CORONARY STENOSIS; EVIDENCE-BASED MEDICINE; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84900404138     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003583     Document Type: Article

References (56)

1. Mangiacapra F, Barbato E. From SYNTAX to FAME, a paradigm shift in revascularization strategies: the key role of fractional fow reserve in guiding myocardial revascularization. J Cardiovasc Med (Hagerstown). 2011;12:538-542.
2. Park SJ, Ahn JM. Should we be using fractional fow reserve more routinely to select stable coronary patients for percutaneous coronary intervention? Curr Opin Cardiol. 2012;27:675-681.
3. Puymirat É, Muller O, Sharif F, Dupouy P, Cuisset T, de Bruyne B, Gilard M. Fractional fow reserve: concepts, applications and use in France in 2010. Arch Cardiovasc Dis. 2010;103:615-622.
4. van de Hoef TP, Meuwissen M, Escaned J, Davies JE, Siebes M, Spaan JA, Piek JJ. Fractional fow reserve as a surrogate for inducible myocardial ischaemia. Nat Rev Cardiol. 2013;10:439-452.
5. Ntalianis A, Trana C, Muller O, Mangiacapra F, Peace A, De Backer C, De Block L, Wyffels E, Bartunek J, Vanderheyden M, Heyse A, Van Durme F, Van Driessche L, De Jans J, Heyndrickx GR, Wijns W, Barbato E, De Bruyne B. Effective radiation dose, time, and contrast medium to measure fractional fow reserve. JACC Cardiovasc Interv. 2010;3:821-827.
6. Hoole SP, Seddon MD, Poulter RS, Mancini GB, Wood DA, Saw J. Fame comes at a cost: a Canadian analysis of procedural costs in use of pressure wire to guide multivessel percutaneous coronary intervention. Can J Cardiol. 2011;27:262.e1-262.e2.
7. Taylor CA, Fonte TA, Min JK. Computational fuid dynamics applied to cardiac computed tomography for noninvasive quantifcation of fractional fow reserve: scientifc basis. J Am Coll Cardiol. 2013;61:2233-2241.
8. Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, Erglis A, Lin FY, Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB, Malpeso J, Mancini GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic accuracy of fractional fow reserve from anatomic CT angiography. JAMA. 2012;308:1237-1245.
9. Rochitte CE, George RT, Chen MY, Arbab-Zadeh A, Dewey M, Miller JM, Niinuma H, Yoshioka K, Kitagawa K, Nakamori S, Laham R, Vavere AL, Cerci RJ, Mehra VC, Nomura C, Kofoed KF, Jinzaki M, Kuribayashi S, de Roos A, Laule M, Tan SY, Hoe J, Paul N, Rybicki FJ, Brinker JA, Arai AE, Cox C, Clouse ME, Di Carli MF, Lima JA. Computed tomography angi-ography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography: the CORE320 study [published online ahead of print November 19, 2013]. Eur Heart J. doi: 10.1093/eurheartj/eht488. http://eurheartj. oxfordjournals.org/content/early/2013/11/19/eurheartj.eht488.long. Accessed November 19, 2013.
10. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional fow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224.
11. Gould KL, Johnson NP, Bateman TM, Beanlands RS, Bengel FM, Bober R, Camici PG, Cerqueira MD, Chow BJ, Di Carli MF, Dorbala S, Gewirtz H, Gropler RJ, Kaufmann PA, Knaapen P, Knuuti J, Merhige ME, Rentrop KP, Ruddy TD, Schelbert HR, Schindler TH, Schwaiger M, Sdringola S, Vitarello J, Williams KA Sr, Gordon D, Dilsizian V, Narula J. Anatomic versus physiologic assessment of coronary artery disease: role of coronary fow reserve, fractional fow reserve, and positron emission tomography imaging in revas-cularization decision-making. J Am Coll Cardiol. 2013;62:1639-1653.
12. Navare SM, Mather JF, Shaw LJ, Fowler MS, Heller GV. Comparison of risk stratifcation with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol. 2004;11:551-561.
13. Marie PY, Danchin N, Durand JF, Feldmann L, Grentzinger A, Olivier P, Karcher G, Juillière Y, Virion JM, Beurrier D. Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. Incremental prognostic value compared with clinical, exercise testing, catheterization and radionuclide angiographic data. J Am Coll Cardiol. 1995;26:879-886.
14. Pollock SG, Abbott RD, Boucher CA, Beller GA, Kaul S. Independent and incremental prognostic value of tests performed in hierarchical order to evaluate patients with suspected coronary artery disease: validation of models based on these tests. Circulation. 1992;85:237-248.
15. Berman DS, Hachamovitch R. Risk assessment in patients with stable coronary artery disease: incremental value of nuclear imaging. J Nucl Cardiol. 1996;3(pt 2):S41-S49.
16. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival beneft associated with revascular-ization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900-2907.
17. Chang SM, Nabi F, Xu J, Peterson LE, Achari A, Pratt CM, Mahmarian JJ. The coronary artery calcium score and stress myocardial perfusion imaging provide independent and complementary prediction of cardiac risk. J Am Coll Cardiol. 2009;54:1872-1882.
18. Schenker MP, Dorbala S, Hong EC, Rybicki FJ, Hachamovitch R, Kwong RY, Di Carli MF. Interrelation of coronary calcifcation, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study. Circulation. 2008;117:1693-1700.
19. Hulten EA, Carbonaro S, Petrillo SP, Mitchell JD, Villines TC. Prognostic value of cardiac computed tomography angiography: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;57:1237-1247.
20. Papanicolaou MN, Califf RM, Hlatky MA, McKinnis RA, Harrell FE Jr, Mark DB, McCants B, Rosati RA, Lee KL, Pryor DB. Prognostic implications of angiographically normal and insignifcantly narrowed coronary arteries. Am J Cardiol. 1986;58:1181-1187.
21. Johnson BD, Shaw LJ, Pepine CJ, Reis SE, Kelsey SF, Sopko G, Rogers WJ, Mankad S, Sharaf BL, Bittner V, Bairey Merz CN. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J. 2006;27:1408-1415.
22. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS. Long-term prognosis associated with coronary calcifcation: observations from a registry of 25, 253 patients. J Am Coll Cardiol. 2007;49:1860-1870.
23. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:312-319.
24. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
25. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5:476-490.
26. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller G V, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283-1291.
27. Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, Dada M, Mancini GB, Hayes SW, O'Rourke RA, Spertus JA, Kostuk W, Gosselin G, Chaitman BR, Knudtson M, Friedman J, Slomka P, Germano G, Bates ER, Teo KK, Boden WE, Berman DS. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J. 2012;164:243-250.
28. Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, Pop-Busui R, Taillefer R, Chaitman BR, Gibbons RJ, Heo J, Iskandrian AE. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19:658-669.
29. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee KL, Borges-Neto S, Farsky PS, Jones RH, Berman DS, Bonow RO. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2013;61:1860-1870.
30. Aldweib N, Negishi K, Hachamovitch R, Jaber WA, Seicean S, Marwick TH. Impact of repeat myocardial revascularization on outcome in patients with silent ischemia after previous revascularization. J Am Coll Cardiol. 2013;61:1616-1623.
31. Mancini GB, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE. Predicting outcome in the COURAGE trial: coronary anatomy versus ischemia. JACC Cardiovasc Interv. 2014;7:195-201.
32. Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232-240.
33. Torosoff MT, Sidhu MS, Boden WE. Impact of myocardial ischemia on myocardial revascularization in stable ischemic heart disease: lessons from the COURAGE and FAME 2 trials. Herz. 2013;38:382-386.
34. Arbab-Zadeh A. Stress testing and non-invasive coronary angiography in patients with suspected coronary artery disease: time for a new paradigm. Heart Int. 2012;7:e2.
35. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation. 2012;125:1147-1156.
36. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004-2013.
37. Stuart RJ Jr, Ellestad MH. National survey of exercise stress testing facilities. Chest. 1980;77:94-97.
38. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res. 1990;24:1020-1023.
39. Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler G. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109:1371-1378.
40. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL; STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607-1616.
41. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bär F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignifcant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49:2105-2111.
42. Fearon WF, Tonino PAL, De Bruyne B, Siebert U, Pijls NHJ. Rationale and design of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) study. Am Heart J. 2007; 154: 632-636.
43. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B; FAME Study Investigators. Fractional fow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56:177-184.
44. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfnkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N; Joint ESC/ACCF/AHA/WHF Task Force for the Redefnition of Myocardial Infarction. Universal defnition of myocardial infarction. Circulation. 2007;116:2634-2653.
45. Prasad A, Gersh BJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Pocock SJ, McLaurin BT, Cox DA, Lansky AJ, Mehran R, Stone GW. Prognostic signifcance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54:477-486.
46. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional fow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.
47. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
48. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
49. Boden WE. Which is more enduring-FAME or COURAGE? N Engl J Med. 2012;367:1059-1061.
50. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE, Mancini GB; COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677-687.
51. Lopez de Sa E, Lopez-Sendon J, Rubio R, Delcan JL. Validity of different classifcations of unstable angina. Rev Esp Cardiol. 1999; 52(suppl 1):46-54.
52. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfeld PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams S V, Anderson JL; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354-e471.
53. Katz MH. Evolving treatment options in coronary artery disease. JAMA Intern Med. 2014;174:231.
54. Topol EJ, Nissen SE. Our preoccupation with coronary luminology: the dissociation between clinical and angiographic fndings in ischemic heart disease. Circulation. 1995;92:2333-2342.
55. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG; Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
56. Chan PS, Patel MR, Klein LW, Krone RJ, Dehmer GJ, Kennedy K, Nallamothu BK, Weaver WD, Masoudi FA, Rumsfeld JS, Brindis RG, Spertus JA. Appropriateness of percutaneous coronary intervention. JAMA. 2011;306:53-61.